Phase II study of a 10-valent pneumococcal protein D conjugate vaccine formulation in Gambian children and infants

Phase 2, randomised, single-blind trial of 10Pn-PD-DiT-dPly-PhtD in pneumococcal disease and Haemophilus influenzae disease (3 arms), sponsored by GSK. Primary endpoint: Occurrence of each grade 3 solicited local and general adverse event related to vaccination.